Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May;63(5):720–726. doi: 10.2967/jnumed.121.262485

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

PMC Copyright notice

FIGURE 3. — A 77-y-old man with metastatic melanoma treated with pembrolizumab. CT and fused ¹⁸F-FDG PET/CT images (left) acquired at approximately 8 mo after initiation of immunotherapy demonstrate 2 ¹⁸F-FDG–avid nodal metastases in right neck (SUV_MAX = 8.0, top image; SUV_MAX = 16.8, bottom image), which could represent viable metastases. Corresponding CT and fused CD8 PET/CT images (right) obtained at 1 mo after ¹⁸F-FDG PET/CT demonstrate significant tracer activity in both metastases (SUV_MAX = 5.4, top image; SUV_MAX = 14.6, bottom image), which suggests that some of the ¹⁸F-FDG activity could be due to tumor-infiltrating CD8+ T cells rather than tumor cells. Follow-up imaging over the next 6 mo demonstrated stable disease, supportive of this hypothesis.